Infliximab treatment in pathology-confirmed neurosarcoidosis

Conclusion
Infliximab is an effective treatment in neurosarcoidosis leading to remission or improvement in 70%. The mortality rate in infliximab-treated patients was substantial, indicating the severity of disease and treatment-associated complications.

Classification of evidence
This study provides Class IV evidence that in people with pathology-confirmed neurosarcoidosis, infliximab is beneficial.

Source: Neurology Neuroimmunology and Neuroinflammation - July 26, 2020 Category: Neurology Authors: Fritz, D., Timmermans, W. M. C., van Laar, J. A. M., van Hagen, P. M., Siepman, T. A. M., van de Beek, D., Brouwer, M. C. Tags: All Immunology, Class IV, Cohort studies Article Source Type: research